Novavax (NVAX) : Analyst Rating Update

Novavax (NVAX) has an average broker rating of 1.33, which is interpreted as a Strong Buy, as rated by 6 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Novavax (NVAX) : Currently there are 6 street experts covering Novavax (NVAX) stock. The most bullish and bearish price target for the stock is $17 and $6 respectively for the short term. The average price target of all the analysts comes to $13.15. The estimated standard deviation from the target is $3.81.

Novavax (NASDAQ:NVAX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.18 and $7.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.47. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.46, notching a gain of 3.18% for the day. The total traded volume was 3,957,602 . The stock had closed at $7.23 on the previous day.

Also, Chardan Capital initiates coverage on Novavax (NASDAQ:NVAX) In a research note issued to the investors, the brokerage major announces price-target of $5.75 per share.The shares have been rated Neutral. The rating by the firm was issued on April 4, 2016. The company shares have dropped -33.73% from its 1 Year high price. On Aug 11, 2015, the shares registered one year high at $15.01 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $6.33 and the 200 Day Moving Average price is recorded at $5.75.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *